McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
The U.S. Department of Justice is conducting a criminal investigation into the consulting firm McKinsey & Company for its role in advising major opioid manufacturers on increasing sales. The investigation also focuses on potential obstruction of justice related to McKinsey's consulting records for opioid producers.
美國司法部正在對諮詢公司麥肯錫公司進行刑事調查，調查該公司在建議主要阿片類藥物製造商增加銷售方面所起的作用。該調查還側重於與麥肯錫阿片類藥物生產商諮詢記錄有關的潛在司法障礙。
What Happened: The investigation, which has been ongoing for several years, has led to the formation of a grand jury in Virginia. The U.S. attorney's offices in the Western District of Virginia and the District of Massachusetts are jointly conducting the probe, reported The Wall Street Journal citing people familiar with the investigation.
發生了什麼：這項調查已經持續了好幾年，導致弗吉尼亞州成立了大陪審團。《華爾街日報》援引熟悉調查的人士的話報道，弗吉尼亞西區和馬薩諸塞特區的美國檢察官辦公室正在聯合進行調查。
The criminal investigation revolves around McKinsey's advice to pharmaceutical clients, including Purdue, Endo International, and Mallinckrodt, which previously triggered a wave of civil litigation against the firm. McKinsey reached a $642 million settlement with all 50 states and other entities in 2021, without admitting wrongdoing.
刑事調查圍繞麥肯錫向包括普渡大學、遠藤國際和馬林克羅特在內的製藥客戶提供的建議展開，這些建議此前曾引發過針對該公司的民事訴訟浪潮。麥肯錫在2021年與所有50個州和其他實體達成了6.42億美元的和解協議，但沒有承認有不當行爲。
The firm's former clients, Purdue, Endo, and Mallinckrodt, filed for bankruptcy while facing mass lawsuits alleging they sold drugs through misleading marketing practices, exacerbating addiction. McKinsey helped Purdue develop an initiative to boost OxyContin sales, including advising the company to focus on high-volume prescribers.
該公司的前客戶普渡大學、遠藤大學和馬林克羅特在面臨大規模訴訟時申請破產，指控他們通過誤導性的營銷行爲出售毒品，加劇了成癮。麥肯錫幫助普渡大學制定了一項促進奧施康定銷售的計劃，包括建議該公司將重點放在大批量處方藥上。
McKinsey has previously stated that it ceased work on opioid-specific businesses in 2019 and that its work for Purdue was intended to support the legal use of opioids and patients with legitimate medical needs.
麥肯錫此前曾表示，它於2019年停止了阿片類藥物特定業務的工作，其在普渡大學的工作旨在支持阿片類藥物的合法使用和有合法醫療需求的患者。
McKinsey did not immediately respond to Benzinga's request for comment.
麥肯錫沒有立即回應本辛加的置評請求。
Why It Matters: The criminal investigation into McKinsey's opioid-related consulting is a significant development in the ongoing legal battle surrounding the opioid epidemic. This investigation follows a series of similar actions against other entities involved in the crisis.
爲何重要：對麥肯錫阿片類藥物相關諮詢的刑事調查是圍繞阿片類藥物流行的持續法律鬥爭的重大進展。這項調查是在針對參與危機的其他實體採取了一系列類似行動之後進行的。
Earlier this year, in a landmark move, Publicis Groupe (OTC:PUBGY) agreed to a $350 million settlement over its alleged role in the opioid crisis. This marked the first time an advertising firm was held accountable for its part in the epidemic.
今年早些時候，陽獅集團（場外交易代碼：PUBGY）同意就其涉嫌參與阿片類藥物危機達成3.5億美元的和解協議，這是一項具有里程碑意義的舉動。這標誌着廣告公司首次被追究其在疫情中所扮演的責任。
Moreover, the Supreme Court temporarily suspended a multi-billion-dollar bankruptcy agreement involving Purdue Pharma, the producer of the opioid OxyContin. This arrangement would have shielded the company's Sackler family owners from civil lawsuits linked to the opioid epidemic.
此外，最高法院暫時中止了涉及阿片類藥物奧施康定生產商普渡製藥公司的數十億美元破產協議。這種安排本來可以保護該公司的薩克勒家族所有者免受與阿片類藥物流行有關的民事訴訟。
Image Via Pixabay
圖片來自 Pixabay
譯文內容由第三人軟體翻譯。